Femtogenix Presents Efficacy and Toxicity Data on Antibody Drug Conjugates Containing New Generation of DNA-binding Therapeutic Payloads

HARPENDEN, England–(BUSINESS WIRE)–Femtogenix Ltd, a UK biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate (ADC) payloads, today announced data verifying the favourable toxicity profile and potent efficacy of its Pyridinobenzodiazepine (PDD) ADC payload platform in tumour cell models. The data was presented by Professor David Thurston, Chief Scientific Officer, Femtogenix, on 11 October at World ADC 2019 in San Diego, CA. ADCs are capable of delive

Click to view original post